EYA2 and breast carcinoma: However, there was no statistically significant association between EYA2 mRNA and clinical outcomes in basal-like breast cancer patients, including OS [HR = 1.49 (0.91–2.45), p = 0.11], RFS [HR = 1.04 (0.81–1.34), p = 0.75], and MFS [HR = 1.52 (0.91–2.55), p = 0.11].